Key Words: cardiac metabolism Ⅲ erythropoietin Ⅲ nitric oxide Ⅲ Akt1/protein kinase B Ⅲ mitochondrial biogenesis T he glycoprotein hormone erythropoietin (EPO) is secreted mainly by the kidneys during hypoxia and anemia to initiate hemoglobin production, regulate RBC maturation, and increase RBC mass. 1 EPO treatment reverses the anemia of chronic kidney disease and improves athletic endurance 2 ; moreover, EPO mitigates ischemic/hypoxic damage in the heart and the brain by activation of the EPO receptor (EpoR), 3 which appears to be widely expressed. 4 Embryonic loss-offunction for EPO or EpoR results in early lethality, 5 and EPO confers neuronal preconditioning effects 5, 6 and stimulates neurogenesis and recovery from stroke. In the cardiovascular system, EPO converts mature endothelial cells to an angiogenic phenotype, 4,7 fosters neovascularization (ie, in diabetes 8 ), and prevents cardiomyocyte apoptosis, 9 all by incompletely understood mechanisms.
T he glycoprotein hormone erythropoietin (EPO) is secreted mainly by the kidneys during hypoxia and anemia to initiate hemoglobin production, regulate RBC maturation, and increase RBC mass. 1 EPO treatment reverses the anemia of chronic kidney disease and improves athletic endurance 2 ; moreover, EPO mitigates ischemic/hypoxic damage in the heart and the brain by activation of the EPO receptor (EpoR), 3 which appears to be widely expressed. 4 Embryonic loss-offunction for EPO or EpoR results in early lethality, 5 and EPO confers neuronal preconditioning effects 5, 6 and stimulates neurogenesis and recovery from stroke. In the cardiovascular system, EPO converts mature endothelial cells to an angiogenic phenotype, 4, 7 fosters neovascularization (ie, in diabetes 8 ), and prevents cardiomyocyte apoptosis, 9 all by incompletely understood mechanisms.
EpoR signaling involves JAK2 (Janus kinase 2) recruitment to the receptor dimer, resulting in tyrosine phosphorylation and the formation of docking sites for SH2 domain-containing proteins such as STAT (signal transducer and activator of transcription) transcription factors and other regulators of cell proliferation and differentiation, including the phosphatidylinositol 3-kinases. 10 In nonerythroid cells, EPO activates JAK/STAT and phosphatidylinositol 3-kinase/Akt (protein kinase B) and also endothelial NO synthase (eNOS). 9, 11 eNOS is involved in regulating mitochondrial biogenesis, which is fundamental for mitochondrial turnover and proliferation (eg, during exercise, cell stress, energy deficits, calorie restriction, and disease mitigation) and is under calcium and redox regulation. [12] [13] [14] [15] Specialized nuclear transcription factors, such as nuclear respiratory factor (NRF)-1 and NRF-2, along with PGC-1 (peroxisome proliferator-activated receptor ␥ coactivator 1) family coactivators are required for mitochondrial gene activation and for mtDNA replication and transcription. This program is also stimulated by Akt, which is known to be activated by EpoR as well as to activate eNOS. This background suggested the novel possibility that EPO induces mitochondrial biogenesis through EpoR-dependent activation of eNOS.
Methods
An expanded Methods section is available in the Online Data Supplement at http://circres.ahajournals.org.
Mice
The studies were approved by the Institutional Animal Care and Use Committee and conducted in young male C57BL/6J, Akt1 Ϫ/Ϫ , eNOS Ϫ/Ϫ , and mitochondrial green fluorescent protein (GFP) reporter mice bred in our vivarium. 16 Mice were injected subcutaneously with human recombinant EPO or an equal volume of 0.9% NaCl once daily for 3 consecutive days, and tissues were removed under general anesthesia at the indicated times.
Microscopy
Formalin-fixed and paraffin-embedded tissue blocks were sectioned (5 mol/L), mounted on glass slides, and deparaffinized. Laserscanning confocal microscopy was performed on a Zeiss LSM 410 microscope and fluorescence imaging on a Nikon microscope through a 520 nm filter. The fluorescence signals were quantified using computer software.
Proteins
Cardiac proteins were resolved by SDS-PAGE and transferred to poly(vinylidene difluoride) membranes and probed with primary antibodies (Santa Cruz Biotechnology, Santa Cruz, Calif). After application of the primary antibody, the membranes were washed and incubated with horseradish peroxidase-conjugated secondary antibodies (Santa Cruz Biotechnology and Jackson) and developed in ECL (Santa Cruz Biotechnology), and densitometry was performed on digitized images. At least 4 samples were used at each time point. Pooled cardiac mitochondria were prepared and respiration measured at 35°C 17 using calibrated Clark mini-electrodes (Diamond General, Ann Arbor, Mich). 18 
RNA and DNA
Cytoplasmic RNA was isolated and cDNA synthesized using the Invitrogen SUPERSCRIPT System. Cardiac mtDNA was isolated using NaI kits. Mouse-specific primers and probes were designed as reported 19 RNA samples (1 g) were reverse-transcribed, and gene transcripts were amplified in triplicate with gene-specific primers 19, 20 and quantified by densitometry normalized to 18S rRNA or GAPDH. mtDNA copy number was determined as reported. 21 
Metabolic Measurements
Steady-state O 2 consumption and CO 2 production (V O 2 and V CO 2 ) were measured in resting mice at the same time of day 13 in individual metabolic chambers by collecting expired gas at a timed flow rate. Mitochondrial density and distribution in mitochondrial reporter mouse tissues. Reporter mice expressing a GFP-labeled mitochondrial localization sequence received EPO (4000 U/kg per day) for 3 consecutive days, and the sections were compared by fluorescence microscopy before and after 3 days of EPO administration. Before EPO, green punctuate fluorescence, representing mitochondria, was present diffusely and staining was enhanced in sporadic clusters of cells. After EPO, the heart showed intense green fluorescence throughout the myocardium (A and B) . More focal and less pronounced responses were found in skeletal muscle (C and D), kidney (E and F), and liver (G and H). Scale bars: 10 m. 
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Voluntary Exercise
Mice were housed individually in cages containing rodent exercise wheels 23 equipped with a digital magnetic counter activated by wheel rotation. To limit the variability in time spent running, individual mice were observed initially for 72 hours and then assigned randomly to groups that were well-matched for running times. One group received injections of EPO, and the other NaCl, and running duration, running speed, and distance in kilometers were recorded daily.
Transthoracic Echocardiography
Mice were lightly anesthetized with 1.5% isoflurane, and the measurements were made with a 707B 30-MHz ultrasonic probe and recorded on a VEVO 770 System (VisualSonics Inc, Toronto, Canada).
Statistics
Grouped data (nϭ4 to 6) were expressed as meansϮSEM. Statistical analyses were by 2-way or repeated measures ANOVA using StatView (version 5.0.1; SAS Institute, Chicago, Ill). PϽ0.05 was considered significant.
Results
Mitochondrial Biogenesis in Reporter Mice Before and After EPO
The distribution and mass of mitochondria in the tissues of mitochondrial-targeted GFP reporter mice were examined before and after EPO administration ( Figure 1 ). In reporter mice before EPO, most of the tissues demonstrated fairly uniform, low-intensity, green fluorescence with rare bright cells containing abundant mitochondria. After 3 days of EPO administration, however, the heart showed intense mitochondrial fluorescence throughout the myocardium ( Figure 1A an 1B), whereas the other tissues showed modest, nonuniform enhancement of mitochondrial fluorescence, eg, skeletal mus- . B, EpoR localization in mouse hearts before and after EPO treatment (red fluorescence) with DAPI nuclear counterstain (blue). C, EPO activation of Akt1 in mouse heart. Phospho-/total Akt was increased in Wt heart after 3 days of EPO administration and fell to control by day 14. Phospho-/total Akt was unresponsive to EPO in eNOS Ϫ/Ϫ mice. Negative control are heart tissue from Akt1 Ϫ/Ϫ mice probed with anti-pAkt-and anti-Akt1-specific antibodies. D, Phospho-/total ERK1/2 activation in Wt, eNOS Ϫ/Ϫ , and Akt1
hearts, before and after 3 days of EPO administration. E, HO-1 protein expression in Wt, eNOS Ϫ/Ϫ , and Akt1 Ϫ/Ϫ mouse hearts. MeansϮSEM hemoglobin values in g/dL (nϭ4 -9 Wt mice) measured after exposure to 18 000 feet (0.5 ATA) of altitude for 0, 7, or 14 days or after the 3-day EPO regimen (values in parentheses; *PϽ0.05 vs day 0).
cle blood vessels ( Figure 1C and 1D ), renal tubules ( Figure  1E and 1F), and hepatocytes ( Figure 1G and 1H) . Quantitatively, after 3 days of EPO administration, mean cardiomyocyte fluorescence increased 2.8-fold from 36.6Ϯ5.8 to 102.5Ϯ8.0 U/m. 2 Because mitochondrial turnover in the heart requires approximately a week, 24 we examined cardiac interfibrillar and subsarcolemmal mitochondria at higher resolution at day 7. These micrographs demonstrated an EPO effect on both populations, but in some subsarcolemmal areas mitochondrial density and giant mitochondria formation were especially prominent (Online Figure I) . To confirm the increase in mitochondrial mass in the reporter mice, immunofluorescence microscopy was performed for citrate synthase before and after EPO administration. Cardiac colocalization of citrate synthase with GFP expression (yelloworange) before and after EPO administration demonstrated strong overlap in the staining before and after EPO administration (Online Figure II) . strains, but lagged behind in the Akt1 Ϫ/Ϫ mice. In Wt mice, EpoR transcript levels in the heart tripled after 3 days of EPO administration and returned to control by day 14 (Figure 2A) . EpoR protein at baseline was detected by immunofluorescence in vascular endothelium and cardiomyocyte plasma membranes, but this labeling was sharply enhanced by EPO administration ( Figure 2B ).
EPO Responses in
To assess EpoR signaling, cardiac Akt phosphorylation was examined and Akt1 Ser473 and was found to increase on day 3 of EPO administration and return to control by day 7 ( Figure 2C ). In eNOS Ϫ/Ϫ mice, Akt1 was not activated after EPO administration ( Figure 2C shows 2 Akt Western blots; middle blot shows day 3 after EPO administration with antibodies to total and phospho-Akt; right blot shows pre-EPO and after 3, 7, and 14 days of EPO administration using Akt1-specific antibodies). Extracellular signal-regulated kinase (ERK)1/2 was strongly activated by EPO in Wt mice but was activated minimally in Akt1 Ϫ/Ϫ mice ( Figure 2D ). EPO also induced heme oxygenase (HO)-1 protein, which is involved in the regulation of cardiac mitochondrial biogenesis. 25 HO-1 expression, like Akt, was highest in Wt mice at Figure 2E ). HO-1 was also increased in eNOS Ϫ/Ϫ mice but not in Akt1 Ϫ/Ϫ mice ( Figure 2E ). EPO thus exploits eNOS in the heart to activate Akt and ERK1/2, and Akt1 acts upstream of ERK1/2 and HO-1.
Respiration, REE, and Voluntary Exercise
EPO did not affect mitochondrial RCR in the heart, but at day 3 after EPO administration, state 3 respiration increased significantly ( Figure 3A, left) , accompanied by Ϸ30% increases in REE ( Figure 3A , right) at days 7 and 10 (PϽ0.05). Compared with Wt mice, basal REE was marginally depressed in Akt1 Ϫ/Ϫ mice (Pϭ0.06) and did not respond to EPO ( Figure 3A, right) . REE was checked in 2 eNOS Ϫ/Ϫ mice and predictably did not respond to EPO, so this experiment was not repeated.
Voluntary exercise in untrained Wt mice was quantified over 2 weeks using ergometer-calibrated running wheels. Typically, most sedentary mice allowed to run ad libitum over this interval will increase distance and running time at constant speed. 23 Control and EPO-treated mice demonstrated comparable running distances ( Figure 3B ), but during the second week, EPO-treated mice spontaneously covered the same distances in less time (PϽ0.05; Figure   3B , right) but did not significantly increase their total running distance.
Post-EPO Transcriptional Activation of Cardiac Mitochondrial Biogenesis
EPO stimulated the expression of cardiac regulatory genes for mitochondrial biogenesis, including NRF-1, the PGC-1␣ coactivator, and mitochondrial transcription factor-A (Tfam) ( Figure 3C ). NRF-1, PGC-1␣, and Tfam mRNA increased 4-fold on day 3 after EPO administration and returned to control by day 14, whereas mtDNA copy number doubled (Figure 3C, right; PϽ0.05) .
NRF-1, PGC-1␣, and Tfam mRNA levels did not respond to EPO in eNOS Ϫ/Ϫ or Akt1 Ϫ/Ϫ mice, and mtDNA copy number was unaffected ( Figure 4A and 4B) , establishing the requirement for eNOS. SOD2 transcript levels also increased after EPO in Wt but not in eNOS Ϫ/Ϫ or Akt1 Ϫ/Ϫ mice ( Figure 4C ).
Cardiac Ultrasonography
Cardiac chamber size, wall thickness, and function were evaluated in Wt mice by echocardiography at day 0 and at day 7 after EPO administration. A small increase in intraventric- Ϫ/Ϫ mice. C, SOD2 mRNA expression in Wt mouse heart before and after EPO (left) and before and after 3 days of EPO in Wt, eNOS
, and Akt1
Ϫ/Ϫ mice relative to GAPDH (right) (*PϽ0.05 vs control; nϭ4). ular septal diameter in diastole was noted after EPO, but no changes in left ventricular mass index or in fractional shortening at comparable heart rates ( Table 2) .
Studies of Isolated Cardiomyocytes
To investigate the requirement for EpoR, we selected NRF-1 for examination, which activates more than 100 genes involved in mitochondrial biogenesis, including the genes necessary for mtDNA replication. By immunofluorescence, NRF-1 was localized mainly to the cytoplasm of control H9C2 cardiomyocytes ( Figure 5A through 5C ), whereas after EPO ( Figure 5D through 5F), NRF-1 staining was found primarily in nuclei. After EpoR knockdown (small interfering [si]RNA data not shown), NRF-1 protein did not accumulate in the nucleus after EPO, and NRF-1 remained sequestered in the cytoplasm (Figure 5G through 5I) .
Discussion
The novel aspects of this work disclose that EPO stimulates cardiac mitochondrial proliferation through a highly regulated, receptor-mediated, eNOS/Akt1-dependent cascade that activates the transcriptional program of mitochondrial biogenesis. This activity occurs over approximately 3 to 7 days in mice and leads to a higher state 3 respiration, REE, and running speed in advance of a rising hematocrit, which increases at 1% to 2% per day. Although the EPO response requires eNOS, 26 the sites of microvascular NO production and NO signaling on a paracrine or a cell-by-cell basis were not evaluated; however, we did detect an unexplained increase after EPO in EpoR receptor density in the heart and in cardiomyocytes 27 but found no short-term structural evidence of left ventricular hypertrophy.
The interpretation of these studies has some limitations. We did not formally assess vascular EpoR expression or changes in capillarity in the heart, and although changes in capillary density after EPO have been reported 10 ; such responses, if present here, could not be definitively linked to EpoR-mediated regulation of mitochondrial biogenesis at our present level of resolution. In terms of metabolism, the heart in resting mice consumes Ϸ30% of the O 2 with a welldefined preference for myocardial ␤-oxidation over glucose oxidation. Higher complex II activity would help support the reoxidation of FADH 2 (flavin adenine dinucleotide), which requires more O 2 , but this could quantitatively account for the higher REE only if resting myocardial O 2 utilization had doubled. Thus, it is likely that respiration in other organs contributed a modest but unknown amount to the increase in REE. 4, 27 Similar constraints apply to the interpretation of the spontaneous exercise data, which demonstrate effectiveness for our EPO protocol, but where the roles of eNOS, Akt1, and changes in skeletal muscle oxidative capacity were not assessed. Skeletal muscle fiber type switching would also be of interest but could reflect the modified submaximal exercise behavior and not a direct effect of EPO, which, among other factors, would depend on EpoR activity in skeletal muscle. Finally, the abundant response by subsarcolemmal mitochondria was not investigated in detail, but these mitochondrial populations do serve different cellular functions and are differently regulated. Overall, however, there is good temporal and quantitative correlation among the molecular, functional, and structural manifestations of cardiac mitochondrial biogenesis after EPO administration.
The therapeutic potential of EPO in acute coronary and cerebral ischemia 28 involves antiapoptotic, antiinflammatory, and angiogenic effects 28, 29 for which the prosurvival serine/ threonine kinase Akt1/2 is a key effector. 11 Here, Akt1 was required for EPO to stimulate cardiac mitochondrial biogenesis, in keeping with the activating role of Akt/NRF-1 mitochondrial biogenesis. 14, 30 The transcriptional program is also activated by eNOS, 15, 26, 31 and, as an aside, we note that eNOS must be active for EPO to prevent apoptosis and limit experimental cardiac infarct size. 9 EPO-induced mitochondrial biogenesis conforms to eNOS-inducible metabolic gene regulation, eg, by CREB (cAMP-responsive element-binding protein), and the requirement for Akt1 fits its role in growth, metabolism, and cell survival. Also, Akt, eNOS, and HO-1 exhibit an elaborate integration: Akt activates eNOS by calcium-independent phosphorylation, 32 and NO activates phosphatidylinositol 3-kinase, an important Akt regulator, and under some conditions, Akt itself. 33 The Wt and eNOS Ϫ/Ϫ mice also upregulate HO-1, the latter without new mitochondrial biogenesis, implying that HO-1 is upstream of eNOS in this case.
The physiological responses to EPO are conventionally attributed to hemoglobin biosynthesis and erythropoiesis, which increase red cell mass, and thus hematocrit and arterial O 2 content (CaO 2 ). 27, 34 In erythroid progenitor cells, EPO is also involved in the regulation of iron uptake through the posttranscriptional induction of transferrin receptor. 35 EPO also directly stimulates the transcriptional and posttranscriptional expression of 5-aminolevulinic acid synthase (ALAS-E), which resides in mitochondria and is the rate-limiting step in heme biosynthesis 36 and necessary for cytochrome assembly. Clinically, EPO treatment mitigates the anemia of chronic kidney disease, although EPO increases mortality in cancer patients 37 and when the target hemoglobin is set too high. 38 In human athletes, EPO enhances endurance by improving maximum O 2 uptake in direct relation to hematocrit 34 ; however, a role for EPO in maintaining cardiac function in hypoxia and anemia, the main settings for its production, although long suspected, has been unconfirmed.
In the context of hypoxia, the regulation of cardiac mitochondrial density by EPO implies that a distinct spatial and functional arrangement of the organelles is necessary for optimal aerobic work performance at steady-state convective oxygen transport (cardiac output times CaO 2 ) as hematocrit, the principal determinant of blood viscosity, increases. Because blood viscosity is governed by hematocrit (at constant shear rate), the inherent matching of cardiac mitochondrial mass to erythrocyte O 2 carrying capacity, despite the heart's normally high oxygen extraction ratio, and barring limitations in coronary blood flow, would serve to protect cardiac oxidative phosphorylation and therefore maintain peripheral tissue O 2 delivery during hypoxia. By comparison, in anemia of nonrenal origin, the cardiac structure-function implications are less clear because endogenous EPO secretion tends to be elevated and it is not known whether mitochondrial volume density is affected.
In conclusion, cardiac EpoR activation after EPO administration activates mitochondrial biogenesis in normal mice before significant increases in circulating hemoglobin concentration. Ultimately, the physiological increase in mitochondrial density serves aerobic cardiac performance at a higher blood viscosity, but the effectiveness of this would be contingent on a higher myocardial O 2 uptake stemming from an adjustment in aerobic capacity for contractile function designed for use in hypoxia. 6, 11, 39 In addition to the new physiological role for EPO, our findings have latent implications for the treatment of patients with ischemic cardiomyopathy and anemia, often associated with chronic kidney disease, who may be candidates for stabilization of ventricular and renal function by the administration of erythropoietic agents 40 but who may also have myocardium at risk under conditions of an elevated cardiac O 2 demand. H9C2 rat cardiomyocytes were transfected with scrambled (Scr) or EpoR siRNA followed by EPO treatment (1000 U/mL). After 24 hours, fluorescence microscopy was performed using anti-NRF-1 (red) and EpoR (green). A through C, Scrambled RNA pre-EPO. D through F, Scrambled RNA post-EPO. G through I, Post-EPO plus siRNA. Nuclear NRF-1 translocation by EPO requires EpoR expression.
